Table 2. Univariate and multivariate analyses of OS in 57 patients who received a phase I trial therapy.

Potential Risk Factors	Patient Number	Median OS (months, 95% CI)	p value
			Univariate	Multivariate
Age < 65 years	Yes (n=46)	10.1 (5.2-15)	0.121	0.185
	No (n=11)	17.9 (6.7-29.1)
Male	Yes (n=37)	15.2 (6.3-24.1)	0.334	0.228
	No (n=20)	12 (4.1-19.9)
Colorectal cancer	Yes (n=39)	12 (6.6-17.4)	0.773	0.582
	No (n=18)	7.3 (0-16.5
Presence of a second primary cancer	Yes (n=5)	10.1 (0, infinity)	0.086	0.106
	No (n=52)	13 (4.6-21.4)
Metastasis at initial diagnosis	Yes (n=28)	7.3 (4.2-10.4)	0.176	0.978
	No (n=29)	13 (8-18.1)
Number of metastatic sites≤ 2	Yes (n=18)	13 (2.1-23.9)	0.572	0.402
	No (n=39)	10.1 (4.2-16)
Lung metastasis	Yes (n=43)	15.4 (8.3-22.5)	0.015	0.01
	No (n=14)	7.3 (4.5-10.1)
Liver metastasis	Yes (n=41)	8.5 (4.6-12.4)	0.571	0.593
	No (n=16)	15.2 (7-23.4)
Eastern Cooperative Oncology Group (ECOG) performance status of 0	Yes (n=8)	16.6 (3.1-30.1)	0.077	0.66
	No (n=49)	10.1 (3.1-17.1)
Neutrophilia	Yes (n=6)	3.4 (2-4.8)	<0.001	<0.001
	No (n=51)	13 (6.6-19.4)
Lymphopenia	Yes (n=16)	7.3 (1.9-12.7)	0.103	0.386
	No (n=41)	13 (7.4-18.6)
Anemia	Yes (n=41)	13 (4.8-21.2)	0.778	0.097
	No (n=16)	10.1 (3.9-16.3)
Thrombocytosis	Yes (n=1)	2.6 (0, infinity)	<0.001	0.022
	No (n=56)	12 (5.5-18.5)
Normal lactate dehydrogenase	Yes (n=33)	15.2 (11.3-19.1)	0.11	0.119
	No (n=24)	6.5 (5-8)
Hypoalbuminemia	Yes (n=2)	2.5 (0, infinity)	0.016	0.029
	No (n=55)	13 (6.2-19.8)
Normal creatinine	Yes (n=56)	12 (5.6-18.4)	0.811	0.984
	No (n=1)	2.7 (0, infinity)
Hyperbilirubinemia	Yes (n=11)	10.1 (4.5-15.7)	0.86	0.039
	No (n=46)	12 (4.2-20)
Venous thromboembolism	Yes (n=12)	12 (3.6-20.4)	0.593	0.281
	No (n=45)	13 (6.8-19.2)
Body mass index (BMI) ≥30 kg/m2	Yes (n=11)	12 (0-26.9)	0.05	0.023
	No (n=46)	10.1 (4.2-16)